TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease:

• To confirm the superiority of TRK-100STP over placebo

• To determine the recommended therapeutic dose in the 2 doses of TRK-100STP

• To assess the safety of TRK-100STP

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toray Industries, Inc
• Collaborator: Astellas Pharma Inc
• Treatments: Beraprost; Epoprostenol

Criteria

Inclusion Criteria:

• The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease

• The patient with progressive CRF

Exclusion Criteria:

• The patient with secondary glomerular disease

• The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis